DK2606068T3 - Kombineret anvendelse af fc gamma riib (cd32b) og cd19-, cd20- eller cd40-specifikke antistoffer - Google Patents

Kombineret anvendelse af fc gamma riib (cd32b) og cd19-, cd20- eller cd40-specifikke antistoffer

Info

Publication number
DK2606068T3
DK2606068T3 DK11760819.0T DK11760819T DK2606068T3 DK 2606068 T3 DK2606068 T3 DK 2606068T3 DK 11760819 T DK11760819 T DK 11760819T DK 2606068 T3 DK2606068 T3 DK 2606068T3
Authority
DK
Denmark
Prior art keywords
cd32b
specific antibodies
combined use
gamma riib
riib
Prior art date
Application number
DK11760819.0T
Other languages
Danish (da)
English (en)
Inventor
Mark Cragg
Martin Glennie
Ali Roghanian
Stephen Beers
Peter Johnson
Sean Lim
Björn Frendeus
Ingrid Teige
Original Assignee
Univ Southampton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southampton filed Critical Univ Southampton
Application granted granted Critical
Publication of DK2606068T3 publication Critical patent/DK2606068T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK11760819.0T 2010-08-20 2011-08-19 Kombineret anvendelse af fc gamma riib (cd32b) og cd19-, cd20- eller cd40-specifikke antistoffer DK2606068T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1013989.7A GB201013989D0 (en) 2010-08-20 2010-08-20 Biological materials and methods of using the same
PCT/GB2011/051572 WO2012022985A1 (en) 2010-08-20 2011-08-19 Combined use of fc gamma riib (cd32b) and cd20 - specific antibodies

Publications (1)

Publication Number Publication Date
DK2606068T3 true DK2606068T3 (da) 2017-11-20

Family

ID=42984443

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11760819.0T DK2606068T3 (da) 2010-08-20 2011-08-19 Kombineret anvendelse af fc gamma riib (cd32b) og cd19-, cd20- eller cd40-specifikke antistoffer

Country Status (17)

Country Link
US (4) US10525129B2 (enExample)
EP (2) EP3263602A1 (enExample)
JP (2) JP6215704B2 (enExample)
KR (1) KR101948609B1 (enExample)
CN (7) CN114099669A (enExample)
AU (1) AU2011290503B2 (enExample)
CA (1) CA2808744C (enExample)
DK (1) DK2606068T3 (enExample)
ES (1) ES2653685T3 (enExample)
GB (1) GB201013989D0 (enExample)
HU (1) HUE037478T2 (enExample)
NO (1) NO2606068T3 (enExample)
PL (1) PL2606068T3 (enExample)
PT (1) PT2606068T (enExample)
RU (2) RU2769949C2 (enExample)
SI (1) SI2606068T1 (enExample)
WO (1) WO2012022985A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201013989D0 (en) * 2010-08-20 2010-10-06 Univ Southampton Biological materials and methods of using the same
WO2014085596A1 (en) * 2012-11-29 2014-06-05 Bayer Healthcare Llc MONOCLONAL ANTIBODIES AGAISNT ACTIVATED PROTEIN C (aPC)
ES2730690T3 (es) * 2012-12-07 2019-11-12 Suppremol Gmbh Estratificación y tratamiento de pacientes que padecen púrpura trombocitopénica idiopática
US10450354B2 (en) 2013-03-12 2019-10-22 Molecular Templates, Inc. CD20-binding immunotoxins for inducing cellular internalization and methods using same
EP2833139A1 (en) * 2013-08-01 2015-02-04 SuppreMol GmbH In vitro method for determining the stability of compositions comprising soluble Fc gamma receptor(s)
KR102692200B1 (ko) 2014-01-27 2024-08-06 몰레큘러 템플레이츠, 인코퍼레이션. 포유류에 적용하기 위한 탈면역된 시가 독소 a 서브유닛 작동체 폴리펩티드
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
GB2526139A (en) * 2014-05-15 2015-11-18 Biolnvent Internat Ab Medicaments, uses and methods
CA2947048C (en) 2014-06-11 2023-10-17 Molecular Templates, Inc. Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeted molecules comprising the same
US10392425B2 (en) 2015-02-05 2019-08-27 Molecular Templates, Inc. Multivalent CD20-binding molecules comprising Shiga toxin A subunit effector regions and enriched compositions thereof
CN107223135B (zh) * 2015-03-16 2021-11-02 亥姆霍兹慕尼黑中心-德国环境健康研究中心(Gmbh) 用于治疗hbv感染和相关病症的三特异性结合分子
RS60441B1 (sr) 2015-05-30 2020-07-31 Molecular Templates Inc De-imunizovane, strukture shiga toksin a podjedinice i ciljani ćelijski molekuli koji sadrže isti
CA3008102A1 (en) 2015-12-18 2017-06-22 Novartis Ag Antibodies targeting cd32b and methods of use thereof
CN114773439A (zh) 2016-12-07 2022-07-22 分子模板公司 用于位点特异性缀合的志贺毒素a亚基效应子多肽、志贺毒素效应子支架和细胞靶向分子
EP3551047A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
AU2018213194B2 (en) 2017-01-25 2023-01-12 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, Shiga toxin A Subunit effectors and CD8+ T-cell epitopes
EP3573640A4 (en) * 2017-01-30 2021-04-28 The Ohio State Innovation Foundation PASSIVE ANTIBODY DEPENDENT CELLULAR MEDIATION ACTIVATION
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2018229706A1 (en) 2017-06-16 2018-12-20 Novartis Ag Combination therapy for the treatment of cancer
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
EP3700933A1 (en) 2017-10-25 2020-09-02 Novartis AG Antibodies targeting cd32b and methods of use thereof
RU2020121458A (ru) 2017-11-30 2021-12-30 Новартис Аг Химерный антигенный рецептор, нацеливающийся на bcma, и его пути применения
WO2019204272A1 (en) 2018-04-17 2019-10-24 Molecular Templates, Inc. Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds
CN108823211A (zh) * 2018-05-04 2018-11-16 中国医学科学院基础医学研究所 一种cd19核酸适配体及其应用
PE20210320A1 (es) 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
US20230023414A1 (en) 2018-11-19 2023-01-26 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CA3147164A1 (en) * 2019-07-17 2021-01-21 Bioinvent International Ab Antibody combinations for treatment of cancer in specific patients
JP7413519B2 (ja) * 2019-10-18 2024-01-15 ジェネンテック， インコーポレイテッド びまん性大細胞型ｂ細胞リンパ腫を処置するための抗ｃｄ７９ｂ免疫抱合体の使用方法
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP3919077A1 (en) 2020-06-04 2021-12-08 BioInvent International AB Model for prediction of tolerability issues in connection with intravenous administration of therapeutic antibodies
KR20230038180A (ko) 2020-06-04 2023-03-17 바이오인벤트 인터내셔날 에이비 정맥 내 투여와 관련된 항체 관용성 개선
AU2021373366A1 (en) 2020-11-06 2023-06-01 Novartis Ag Cd19 binding molecules and uses thereof
TW202336033A (zh) 2022-03-07 2023-09-16 瑞典商生物創新國際有限公司 抗體之新穎組合及用途
TW202346359A (zh) 2022-04-15 2023-12-01 美商凱維那醫療公司 用於治療自體免疫疾病之方法及組合物
US20240261405A1 (en) 2022-06-08 2024-08-08 Kyverna Therapeutics, Inc. Methods and compositions for treating autoimmune disease

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
JPH06507404A (ja) 1991-05-01 1994-08-25 ヘンリー　エム．ジャクソン　ファウンデイション　フォー　ザ　アドバンスメント　オブ　ミリタリー　メディスン 感染性の呼吸性疾患の治療方法
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
JP2000506165A (ja) 1996-03-04 2000-05-23 ザ ペン ステイト リサーチ ファウンデーション 細胞インターナリゼーションを増強するための物質および方法
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
DE69732306T2 (de) 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
JP2002518432A (ja) 1998-06-24 2002-06-25 アドバンスト インハレーション リサーチ，インコーポレイテッド 吸入器から放出される大多孔性粒子
RU2305561C2 (ru) * 1999-11-08 2007-09-10 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием антител против cd40l в комбинации с антителами против cd20 и/или химиотерапией и лучевой терапией
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
US20060177439A1 (en) 2004-12-15 2006-08-10 Scott Koenig FcgammaRIIB-specific antibodies and methods of use thereof
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
WO2005018669A1 (en) * 2003-08-18 2005-03-03 Macrogenics, Inc. Fcϝriib-specific antibodies and methods of use thereof
PT1709073E (pt) 2003-11-26 2011-09-29 Max Planck Gesellschaft Substância que se liga ao receptor fc iib de igg humano (fcgamariib)
CN101001872A (zh) * 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB－特异性抗体及其使用方法
JP5367982B2 (ja) * 2004-04-16 2013-12-11 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体とその利用法
WO2005110474A2 (en) * 2004-05-10 2005-11-24 Macrogenics, Inc. HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
AU2005300261A1 (en) * 2004-05-20 2006-05-11 Imperial College Innovations Limited IgE-retargeting, Function-Altering Molecules (ERFAM) for treatment of allergic diseases
CA2587766A1 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
EP1674479A1 (en) * 2004-12-22 2006-06-28 Memorial Sloan-Kettering Cancer Center Modulation of Fc Gamma receptors for optimizing immunotherapy
EP2032159B1 (en) * 2006-06-26 2015-01-07 MacroGenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
US20120030144A1 (en) * 2007-11-08 2012-02-02 Pikamab, Inc. Methods for doing business using biomarkers
WO2009083009A2 (en) * 2008-01-03 2009-07-09 Genmab A/S Monoclonal antibodies against cd32b
EP2385953A4 (en) 2009-01-08 2012-06-06 Uab Research Foundation METHOD FOR REGULATING IMMUNO REACTIONS
GB201013989D0 (en) * 2010-08-20 2010-10-06 Univ Southampton Biological materials and methods of using the same
GB2526139A (en) 2014-05-15 2015-11-18 Biolnvent Internat Ab Medicaments, uses and methods

Also Published As

Publication number Publication date
JP6215704B2 (ja) 2017-10-18
RU2769949C2 (ru) 2022-04-11
CN114099668B (zh) 2025-10-17
RU2013112345A (ru) 2014-09-27
CN107670034A (zh) 2018-02-09
CN107670034B (zh) 2021-07-20
EP2606068B1 (en) 2017-09-27
CN114099668A (zh) 2022-03-01
CN103080131A (zh) 2013-05-01
US10525129B2 (en) 2020-01-07
EP3263602A1 (en) 2018-01-03
NO2606068T3 (enExample) 2018-02-24
CA2808744C (en) 2023-03-07
JP2016138129A (ja) 2016-08-04
CN114099669A (zh) 2022-03-01
CN114099667A (zh) 2022-03-01
US20210346498A1 (en) 2021-11-11
US20200069798A1 (en) 2020-03-05
RU2017143633A (ru) 2019-02-14
US20130251706A1 (en) 2013-09-26
US11623005B2 (en) 2023-04-11
WO2012022985A1 (en) 2012-02-23
CN114099667B (zh) 2025-10-21
ES2653685T3 (es) 2018-02-08
CA2808744A1 (en) 2012-02-23
CN114099666A (zh) 2022-03-01
PT2606068T (pt) 2017-12-29
CN114099666B (zh) 2025-05-02
AU2011290503B2 (en) 2015-09-03
KR20140005866A (ko) 2014-01-15
GB201013989D0 (en) 2010-10-06
EP2606068A1 (en) 2013-06-26
PL2606068T3 (pl) 2018-03-30
KR101948609B1 (ko) 2019-02-15
RU2017143633A3 (enExample) 2021-01-29
CN114099702B (zh) 2024-08-27
AU2011290503A1 (en) 2013-03-07
SI2606068T1 (en) 2018-01-31
US20230381310A1 (en) 2023-11-30
HUE037478T2 (hu) 2018-08-28
JP2013537547A (ja) 2013-10-03
JP6421140B2 (ja) 2018-11-07
CN114099702A (zh) 2022-03-01

Similar Documents

Publication Publication Date Title
DK2606068T3 (da) Kombineret anvendelse af fc gamma riib (cd32b) og cd19-, cd20- eller cd40-specifikke antistoffer
DK3789038T3 (da) Humaniserede og kimære monoklonale antistoffer mod cd47
DK2785375T3 (da) Anti-pd-l1-antistoffer og anvendelser deraf
DK2812443T3 (da) Cd47-antistoffer og fremgangsmåder til anvendelse deraf
DK2598483T3 (da) Ampk-aktiverende heterocykliske forbindelser og fremgangsmåder til anvendelse af disse
HRP20181360T1 (hr) Anti-cd28 humanizirana protutijela
DK2691443T3 (da) Konjugerede lipomerer og anvendelser af disse
DK3339323T3 (da) Anti-n3pglu-amyloid-beta-peptid-antistoffer og anvendelser deraf
DK2537012T3 (da) Pældetektionsindretning og fremgangsmåde til anvendelse af samme
EP2670733A4 (en) HDAC HEMMER AND THERAPY PROCESS THEREFOR
DK2672979T3 (da) Anti-cd4-antistoffer til forebyggelse af især graft-versus-host-sygdom (gvhd)
EP2915250A4 (en) TRANSMIT ARCHITECTURE AND RELATED METHODS
DK2594567T3 (da) Heterocykliske alkynylbenzenforbindelser og anvendelser deraf
ZA201302334B (en) N-(tetrazol-5-yl)-and n-(triazol-5-yl)arylcarboxamides and use threof as herbicides
EP2600613A4 (en) INTRAPRÄDIKTIONS-DECODING DEVICE
DK3199552T3 (da) Anti-ceacam5-antistoffer og anvendelser heraf
DK3329775T3 (da) Fremgangsmåder til syntese af diarylthiohydantoin- og diarylhydantoinforbindelser
DK2925782T3 (da) Anti-cd47-antistoffer og fremgangsmåder til anvendelse deraf
DK2637690T3 (da) Flydende ANTI-TNF-alpha-antistofformuleringer med høj koncentration
DK2914627T3 (da) Anti-cd40-antistoffer og fremgangsmåder til anvendelse
BR112013002297A2 (pt) anticorpos humanizados seguros e funcionais
DK2668210T3 (da) Anti-kit antistoffer og anvendelser deraf
DK2643782T3 (da) Systemer og fremgangsmåder til bedømmelse af kognitiv funktion
DK4331604T5 (da) Anti-pd-l1-antistoffer og deres anvendelse til at forstærke t-celle-funktion
DK3381943T3 (da) Anti-kit-antistoffer og anvendelser deraf